Abstract
As the number of CA-MRSA skin and soft tissue infections continues to grow, it's important to know which patients are at greatest risk and which evidence-based treatment protocols to turn to when needed.
MeSH terms
-
Acetamides / economics
-
Acetamides / therapeutic use
-
Administration, Topical
-
Anti-Bacterial Agents / economics
-
Anti-Bacterial Agents / therapeutic use
-
Clindamycin / economics
-
Clindamycin / therapeutic use
-
Community-Acquired Infections / diagnosis
-
Community-Acquired Infections / drug therapy
-
Continuity of Patient Care
-
Cross Infection / diagnosis
-
Ethnicity
-
Humans
-
Linezolid
-
Medical History Taking
-
Methicillin-Resistant Staphylococcus aureus / isolation & purification*
-
Mupirocin / administration & dosage
-
Oxazolidinones / economics
-
Oxazolidinones / therapeutic use
-
Patient Education as Topic
-
Physical Examination
-
Practice Guidelines as Topic
-
Rifampin / therapeutic use
-
Risk Factors
-
Secondary Prevention
-
Skin / injuries
-
Staphylococcal Infections / diagnosis*
-
Staphylococcal Infections / drug therapy*
-
Staphylococcal Infections / transmission
-
Trimethoprim, Sulfamethoxazole Drug Combination / economics
-
Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
Substances
-
Acetamides
-
Anti-Bacterial Agents
-
Oxazolidinones
-
Clindamycin
-
Trimethoprim, Sulfamethoxazole Drug Combination
-
Mupirocin
-
Linezolid
-
Rifampin